Several investment firms have updated their stock ratings and price targets on shares of Medivation (NASDAQ: MDVN) in the last week:

  • Medivation had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a $122.00 price target on the stock, up previously from $113.00.
  • Medivation had its price target raised by analysts at Brean Murray from $105.00 to $125.00. They now have a “buy” rating on the stock.
  • Medivation had its price target raised by analysts at William Blair from $119.00 to $134.00. They now have an “outperform” rating on the stock.
  • Medivation had its price target raised by analysts at Credit Suisse from $120.00 to $149.00. They now have an “outperform” rating on the stock.
  • Medivation had its “outperform” rating reaffirmed by analysts at Leerink Swann.
  • Medivation had its “outperform” rating reaffirmed by analysts at Wedbush.

Medivation Inc traded down 2.18% on Friday, hitting $100.93. Medivation Inc has a 52-week low of $15.51 and a 52-week high of $113.00. The company’s market cap is $3.717 billion.

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of small molecule drugs to treat serious diseases for which there are limited treatment options.